2025 HIV Vaccine Science Academy

2025 HIV Vaccine Science Academy

Tue, 3 Jun 2025 - Thu, 5 Jun 2025

8:00am - 5:00pm [CEST]

Cape Town, South Africa

The HIV Vaccine Science Academy aims at supporting early- and mid-career investigators conducting HIV vaccine research in Africa by providing opportunities for training, networking and mentorship. The Academy is designed to support the participants in establishing themselves as independent researchers and team leaders in their respective host institutions, thus contributing to long-term continuity, networking and research ownership in central, eastern, southern and western Africa in the effort to develop a safe and effective HIV vaccine.

The HIV Vaccine Science Academy will welcome 15 fellows and be held in person over three days. 

The academy will serve as a space where participants can interact with leading researchers and experts in the HIV vaccine R&D field. The comprehensive programme will be led by renowned scientists, including vaccine researchers, social scientists, and ethicists. It will use a participative approach to deliver interactive classroom sessions on key topics related to HIV vaccine research and development.

The objectives are to:

  • Provide training on state-of-the-art HIV vaccine research and development, notably vaccine design and the use of relevant scientific tools and skills (such as scientific writing).
  • Provide a unique opportunity to engage and discuss with leaders in the HIV vaccine field, in a retreat-type setting, to build and facilitate collaborations in the search for an HIV vaccine.
  • Support participants in establishing a sustainable network across different research institutions and creating momentum for African led research.

 To be eligible, applicants should:  

  • be proficient in English 
  • be a national and a resident of a western, central, eastern or southern African country 
  • be affiliated with a western, central, eastern or southern African institution 
  • have a letter of support from their home organization 
  • be an early- to mid-career HIV vaccine researcher 

Applications are now open.

Find out more directly from past fellows here.

Please contact enterprise@iasociety.org if you have any questions.

Apply now

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.